Lifitegrast sodium
| Code | Size | Price |
|---|
| TAR-T3977L-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T3977L-50mg | 50mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Lifitegrast sodium (SAR-1118) is an LFA-1 antagonist for the therapy of vascular complications of the eye. It inhibits T cell-mediated inflammation by blocking the binding of two cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), thus reducing overall inflammatory responses.
CAS:
1119276-80-0
Formula:
C29H23Cl2N2NaO7S
Molecular Weight:
637.46
Purity:
0.98
SMILES:
[Na+].CS(=O)(=O)c1cccc(CC(NC(=O)c2c(Cl)cc3CN(CCc3c2Cl)C(=O)c2ccc3ccoc3c2)C([O-])=O)c1
References
Yandrapu S, Kompella UB. Development of sustained-release microspheres for the delivery of SAR 1118, an LFA-1 antagonist intended for the treatment of vascular complications of the eye. J Ocul Pharmacol Ther. 2013 Mar;29(2):236-48. doi: 10.1089/jop.2012.0210. Epub 2012 Dec 20. PubMed PMID: 23256487; PubMed Central PMCID: PMC3601676.
Sheppard JD, Torkildsen GL, Lonsdale JD, D'Ambrosio FA Jr, McLaurin EB, Eiferman RA, Kennedy KS, Semba CP; OPUS-1 Study Group. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014 Feb;121(2):475-83. doi: 10.1016/j.ophtha.2013.09.015. Epub 2013 Nov 26. PubMed PMID: 24289915.
Tauber J, Karpecki P, Latkany R, Luchs J, Martel J, Sall K, Raychaudhuri A, Smith V, Semba CP; OPUS-2 Investigators. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study. Ophthalmology. 2015 Dec;122(12):2423-31. doi: 10.1016/j.ophtha.2015.08.001. Epub 2015 Sep 11. PubMed PMID: 26365210.
Perez VL, Pflugfelder SC, Zhang S, Shojaei A, Haque R. Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease. Ocul Surf. 2016 Jan 22. pii: S1542-0124(16)00010-0. doi: 10.1016/j.jtos.2016.01.001. [Epub ahead of print] Review. PubMed PMID: 26807723.